Long-term efficacy of ibrutinib–venetoclax for first-line treatment in chronic lymphocytic leukaemia

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

(2023) Talha Munir et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

(2023) Barbara Eichhorst et al.   NEW ENGLAND JOURNAL OF MEDICINE

Fixed-duration ibrutinib–venetoclax versus chlorambucil–obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial

(2023) Carsten U Niemann et al.   LANCET ONCOLOGY

Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort

(2022) Constantine S. Tam et al.   BLOOD

Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial

(2022) Constantine S Tam et al.   LANCET ONCOLOGY

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study

(2021) Othman Al-Sawaf et al.   JOURNAL OF CLINICAL ONCOLOGY

Acalabrutinib plus Obinutuzumab in Treatment-Naïve and Relapsed/Refractory Chronic Lymphocytic Leukemia

(2020) Jennifer A. Woyach et al.   Cancer Discovery

Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study

(2019) Jan A. Burger et al.   LEUKEMIA